STRIBILD tenofovir disoproxil fumarate 300mg, emtricitabine 200 mg, elvitegravir 150 mg, cobicistat 150 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

stribild tenofovir disoproxil fumarate 300mg, emtricitabine 200 mg, elvitegravir 150 mg, cobicistat 150 mg tablet bottle

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; silicon dioxide; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-na?ve adults. stribild is also indicated in certain virologically suppressed (hiv1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of stribild (tenofovir df, emtricitabine or elvitegravir). stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Tenofovir disoproxil 245 mg film coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

tenofovir disoproxil 245 mg film coated tablets

accord healthcare ireland ltd. - tenofovir disoproxil - film-coated tablet - 245 milligram(s) - nucleoside and nucleotide reverse transcriptase inhibitors; tenofovir disoproxil

TENOFOVIR DISOPROXIL FUMURATE; EMITRICITABINE; EFAVIRENZ Zimbabwe - English - Medicines Control Authority

tenofovir disoproxil fumurate; emitricitabine; efavirenz

strides arcolab ltd - efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet; oral - 600; 200; 300mg

Tenofovir Disoproxil Fumarate / Emtricitabine Tablets 300 + 200 Tanzania - English - Tanzania Medicinces & Medical Devices Authority

tenofovir disoproxil fumarate / emtricitabine tablets 300 + 200

mylan laboratories limited, india - emtricitabine , tenofovir disoproxil fumarate - tablets - 300 + 200

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL Dispersible Tablet Kenya - English - Pharmacy and Poisons Board

efavirenz, lamivudine and tenofovir disoproxil dispersible tablet

laurus labs limited 2nd floor, serene chambers, road no.-7 banjara - efavirenz, lamivudine and tenofovir disoproxil… - dispersible tablet - efavirenz usp 400 mg, lamivudine usp 300 mg and… - lamivudine tenofovir disoproxil and efavirenz

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL Film-Coated Tablet Kenya - English - Pharmacy and Poisons Board

efavirenz, lamivudine and tenofovir disoproxil film-coated tablet

laurus labs limited 2nd floor, serene chambers, road no.-7 banjara - efavirenz, lamivudine and tenofovir disoproxil… - film-coated tablet - efavirenz 600mg, lamivudine 300mg and tenofovir… - lamivudine tenofovir disoproxil and efavirenz

TRUVADA tenofovir disoproxil fumarate / emtricitabine 300/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

truvada tenofovir disoproxil fumarate / emtricitabine 300/200 mg tablet bottle

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; croscarmellose sodium; titanium dioxide; triacetin; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate; hypromellose - treatment of hiv-1 infection,truvada is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

EVIPLERA tenofovir disoproxil fumarate 300 mg /emtricitabine 200 mg /rilpivirine (as HCl) 25 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

eviplera tenofovir disoproxil fumarate 300 mg /emtricitabine 200 mg /rilpivirine (as hcl) 25 mg tablet bottle

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil fumarate, quantity: 300 mg; rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; polysorbate 20; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; iron oxide red; macrogol 3350; indigo carmine aluminium lake - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna =< 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).